Portfolio — 24 March 2026

The Assistant Minister for Citizenship, Customs and Multicultural Affairs, Mr Julian Hill, spoke in the House on 23 March in support of the Treasury Laws Amendment (Genetic Testing Protections in Life Insurance and Other Measures) Bill 2025, which bans insurers from using genetic test results in life insurance decisions. The contribution was notable for its personal register: Mr Hill described how, after his daughter nearly died from a blood clot in 2017 caused by an interaction between an undetected genetic mutation and an off-label contraceptive pill, a haematologist advised him against being tested himself, on the grounds that a positive result would damage his insurability for life insurance, income protection and travel cover [TA-260323-house-068fade26cde:s087].

He credited Dr Jane Tiller's sustained advocacy as the primary driver of the bill reaching the chamber.

The policy argument Mr Hill advanced was structural: the existing insurance framework created a direct contradiction with stated government health objectives [TA-260323-house-068fade26cde:s087]. Governments actively promote genetic testing and personalised medicine as public health tools, yet the insurance rules simultaneously penalised people who acted on that encouragement and discovered a genetic condition — deterring voluntary participation in genetic research and testing at precisely the moment such research is most needed.

Mr Hill also used the speech to register opposition to a separate but related health policy question: state government moves to allow pharmacists to prescribe contraceptive pills to first-time users [TA-260323-house-068fade26cde:s087]. He cited Victoria's announcement as the most recent example, arguing that first-time prescriptions require the kind of patient history and clinical assessment that pharmacists are not positioned to conduct, and that people with undetected genetic conditions — like his daughter — face real risks when that screening step is bypassed.

He drew a line between that concern and repeat prescriptions, which he supported on the basis that the patient is already stable on a known medication.

The speech threads two distinct policy vectors through a single clinical narrative. The legislative contribution advances a federal instrument — the genetic testing bill — while the pharmacist-prescribing remarks target state-level regulatory changes, signalling Mr Hill's willingness to comment on health system architecture beyond his immediate portfolio responsibilities.

Policy staff should note that the observations dictionary flags several concepts — including Factor V Leiden, deep vein thrombosis risk, commercial conflicts of interest in pharmacy prescribing, and voluntary participation in genetic research — as absent from current tagging, suggesting the speech carries more technical health-policy content than standard classification captures.